Edwin Posadas, MD
Upfront taxane-based chemotherapy with docetaxel improved survival in patients with metastatic prostate cancer, according to phase III findings from the CHAARTED and STAMPEDE trials, but additional findings have shown strong potential with abiraterone acetate (Zytiga) as well, leading physicians to make varying therapy decisions for their patients.
State of the Science Summit™ on Genitourinary Cancers, Posadas discussed the evolution of prostate cancer therapy, including the earlier use of advanced-stage agents and the potential for immunotherapy in the field.
OncLive: How has systemic therapy in prostate cancer changed in the past year?
: Systemic therapy for advanced prostate cancer has really evolved in the past year. Because of the newer studies that are coming forward, what was used in the most advanced settings are now being used in earlier disease states. This is going to temporarily cause a great deal of confusion as we sort things out. It's critical at this point that physicians who are caring for men with advanced prostate cancer know what tools to use and when to use them. Old paradigms of making treatment decisions based on what line of therapy a patient has been on are probably, and thankfully, going away.
... to read the full story